An investor, who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), filed a lawsuit over alleged violations of Federal Securities Laws by Alnylam Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have certain options and for certain investors are short and strict deadlines running. Deadline: November 26, 2018. NASDAQ: ALNY investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
According to the complaint the plaintiff alleges on behalf of purchasers of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) common shares between February 22, 2017 and July 19, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 22, 2017 and July 19, 2018, the defendants made false and/or misleading statements and/or failed to disclose that Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection, and that as a result, Alnylam’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.